Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Progression 56% Recovery 33% Time to viral- 27% Rezk et al. Ivermectin for COVID-19 LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Prospective study of 320 patients in Egypt Lower progression (p=0.064) and faster viral clearance (p=0.01) Rezk et al., Zagazig University Medical J., doi:10.21608/zumj.2021.92746.2329 Favors ivermectin Favors control
miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin
Rezk et al., Zagazig University Medical Journal, doi:10.21608/zumj.2021.92746.2329
Rezk et al., miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin, Zagazig University Medical Journal, doi:10.21608/zumj.2021.92746.2329
Oct 2021   Source   PDF  
  All Studies   Meta
Prospective 320 hospitalized moderate COVID-19+ patients in Egypt, 160 treated with ivermectin, showing lower mortality, improved recovery, and decreased cytokine expression with treatment. All patients were treated with HCQ. 7890/26-8-2020.
risk of death, 80.0% lower, RR 0.20, p = 0.50, treatment 0 of 160 (0.0%), control 2 of 160 (1.2%), NNT 80, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of progression, 55.6% lower, RR 0.44, p = 0.06, treatment 8 of 160 (5.0%), control 18 of 160 (11.2%), NNT 16, 2 weeks, including deaths.
risk of no recovery, 33.4% lower, RR 0.67, p = 0.27, treatment 14 of 145 (9.7%), control 20 of 138 (14.5%), NNT 21, 4 weeks, more patients were lost to followup in the control group.
time to viral-, 27.3% lower, relative time 0.73, p = 0.01, treatment 160, control 160.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rezk et al., 30 Oct 2021, prospective, Egypt, peer-reviewed, 4 authors, dosage 36mg days 1, 3, 6.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Manuscript ID ZUMJ-2108-2329 (R1) DOI 10.21608/zumj.2021.92746.2329 ORIGINAL ARTICLE miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin Noha A. Rezk1 , Ashraf Elsayed Sileem2 , Doaa Mostafa Gad2 , Amr O. Khalil 3 , 1 Medical Biochemistry, Faculty of Medicine, Zagazig University, Egypt. 2 Chest Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 3 Radiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt; *Corresponding Author: Name noha rezk. Affiliation Assistant Professor of Medical Biochemistry, Faculty of Medicine, Zagazig University, Egypt. Phone: +201101255109. Mailing address: Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig 44512, Egypt Email: Submit Date 2021-08-25 21:40:19 Revise Date 2021-10-09 22:56:00 Accept Date 2021-10-30 12:27:57 ABSTRACT Background: The role of Ivermectin in improving the outcome of coronavirus disease of 2019 (COVID-19) symptoms was reported in several studies, while its effect on the pro-inflammatory cytokines triggering the cytokine storm is still not investigated. Method: This study aimed to investigate the role of Ivermectin on the proinflammatory cytokines in Covid-19 patients and correlated the results with the expression of miR-2909, miR-223-3p. Three hundred and twenty hospitalized patients with confirmed moderate-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were selected. The patients were divided into 2 groups: Group I treated with the Egyptian protocol of COVID-19 including (Ivermectin plus hydroxychloroquine). Group II was treated with the Egyptian protocol, including hydroxychloroquine and no Ivermectin. IL-6, IL-1b, procalcitonin, and gene expression of miR-2909, miR-223-3p, and Toll-like receptor 4 were done by real-time Polymerase Chain Reaction (PCR). Results : Patients treated with COVID-19 protocol including Ivermectin showed a significant decrease of cytokines levels (IL-6, IL-1, and procalcitonin), when compared with the other group, the cytokines levels improvement were positively correlated with miR-2029 expression and negatively correlated with the expression of miR-223-3p. Moderate ill COVID-19 patients treated with Ivermectin showed a significant decline in mortality rate and duration of hospital stay. Conclusion: Ivermectin is an effective drug in improving the outcome of SARSCoV-2 patients with a significant decrease in mortality rate through decreasing cytokines expression via controlling miR-2029, miR-233-3p expressions. Keywords: SARS-CoV-2; Ivermectin; miR-223-3p; miR-2029; Covid-19; Cytokines.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop